Seller record · Research vendor

Nootropic Source

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 4 of 8 criteria. S1, prescriber requirement: No clinician evaluation is claimed anywhere on the site, and the only purchase condition stated is a minimum age of eighteen. 3 more criteria also fail; see the table below.

At a glance

Nootropic SourceResearch vendor

4/8criteria passed

Price: Printed on its own pages before sign-up
Sells: research peptides including semaglutide and tirzepatide, SARMs, and 4 more
FDA letters: None on file

Visit Nootropic Source See all eight dispositions

Research vendor. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A research compound seller offering powders, solutions, sprays and peptides, including semaglutide and tirzepatide vials labeled for research use. It states that it synthesizes compounds in laboratories it holds equity in.

Operating entity No legal entity name is printed in the footer, the contact page, the privacy policy or the legal disclaimer.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	FAIL	Nootropic Source's legal disclaimer page
S2	Prescription gating	FAIL	Nootropic Source's checkout
S3	Pharmacy identification	FAIL	Nootropic Source's semaglutide product page
S4	Compounding disclosure	PASS	Nootropic Source's semaglutide product page
S5	Analytical documentation	PASS	Nootropic Source's posted image
S6	Business address	FAIL	Nootropic Source's contact page
S7	Price disclosure	PASS	Nootropic Source's semaglutide product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1FAILNo clinician evaluation is claimed anywhere on the site, and the only purchase condition stated is a minimum age of eighteen.Source: Nootropic Source's legal disclaimer page.

S2FAILA guest checkout reaches payment selection with no eligibility step, starting from the semaglutide page at 90.00 dollars.Source: Nootropic Source's checkout.

S3FAILNo pharmacy is named on any of the 185 product pages or the policy pages, and every product carries research use only labeling.Source: Nootropic Source's semaglutide product page.

S4PASSThe seller offers no compounded drug, and the product page carries research use only labeling above the description.Source: Nootropic Source's semaglutide product page.

S5PASSThree chromatograms are published as public product images, the newest dated 2019, reporting a 99.5343 percent assay on bromantane; neither GLP-1 product carries one.Source: Nootropic Source's posted image.

S6FAILNo street address is printed as text in the footer, on the contact, privacy or legal pages, or on any of the 185 product pages; an address appears only inside a product-gallery image on the seller's own letterhead.Source: Nootropic Source's contact page.

S7PASSThe semaglutide page prints 90.00 dollars for one 3 mg vial, with quantity tiers falling to 70.00 dollars, and no account is required to see it.Source: Nootropic Source's semaglutide product page.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: research peptides including semaglutide and tirzepatide, SARMs, nootropic powders and solutions, sprays, mushroom extracts, capsules.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Nootropic Source

535 sellers pass S1, prescriber requirement

See all 535 on the S1 criterion page — 527 more than shown here.

This seller fails criteria a medical service must meet. The records above belong to sellers that pass S1; some are partner links, disclosed on their records.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.